지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.7
- 수록면
- 551 - 558 (8page)
이용수
초록· 키워드
오류제보하기
Background/Aims: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such as elderly and/or cirrhotic patients, and to elucidate the factors contributing to a sustained virologic response (SVR). Methods: One hundred IFN ineligible patients infected with genotype 1b hepatitis C virus (HCV) were treated. Simeprevir (100 mg) was given orally together with reduced doses of PEG-IFN-α 2a (90 μg), and ribavirin (200 mg less than the recommended dose).
Results: The patients’ median age was 70 years, and 70 patients were cirrhotic. Three patients (3%) discontinued treatment due to adverse events. The SVR rate was 64%.
Factors that significantly contributed to the SVR included the γ-glutamyl transferase and α-fetoprotein levels, interleukin- 28B (IL28B) polymorphism status, and the level and reduction of HCV RNA at weeks 2 and 4. The multivariate analysis showed that the IL28B polymorphism status was the only independent factor that predicted the SVR, with a positive predictive value of 77%. Conclusions: Simeprevir-based triple therapy with reduced doses of PEG-IFN and ribavirin was safe and effective for IFN ineligible patients infected with genotype 1b HCV. IL28B polymorphism status was a useful predictor of the SVR.
목차
등록된 정보가 없습니다.
참고문헌 (28)
참고문헌 신청
Asahina Y / 2010 / Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection / Hepatology 52:518~527
Editors of the Drafting Committee for Hepatitis Management Guidelines: the Japan Society of Hepatology / 2013 / Guidelines for the management of hepatitis c virus infection: first edition, May 2012, The Japan Society of Hepatology / Hepatol Res 43:1~34
Huang CF / 2010 / Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C / J Infect Dis 201:751~759
Bota S / 2013 / Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review / World J Hepatol 5:120~126
Di Marco V / 2007 / Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial / J Hepatol 47:484~491
Editors of the Drafting Committee for Hepatitis Management Guidelines: the Japan Society of Hepatology / 2013 / Guidelines for the management of hepatitis c virus infection: first edition, May 2012, The Japan Society of Hepatology / Hepatol Res 43:1~34
Huang CF / 2010 / Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C / J Infect Dis 201:751~759
Bota S / 2013 / Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review / World J Hepatol 5:120~126
Di Marco V / 2007 / Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial / J Hepatol 47:484~491
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
Gut and Liver
2016 .01
-
Changes in Hematological Parameters with Pegylated Interferon in Chronic Hepatitis C Virus Infected Patients
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection
Gut and Liver
2015 .01
-
Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C
Clinical and Molecular Hepatology
2016 .01
-
Interferon-γ and Interleukin-10 Gene Polymorphisms are not Predictors of Chronic Hepatitis C (Genotype-4) Disease Progression
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
Clinical and Molecular Hepatology
2017 .01
-
Patient acceptability and efficacy of simeprevir and sofosbuvir in hepatitis C after allogeneic stem cell transplantation
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Genotypes of Hepatitis C Virus in Relapsed and Non-respondent Patients and their Response to Anti-Viral Therapy in District Mardan, Khyber Pakhtunkhawa, Pakistan
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China
Gut and Liver
2016 .01
-
Single Nucleotide Polymorphism of Interferon Lambda-4 Gene is not Associated with Treatment Response to Pegylated Interferon in Thai Patients with Chronic Hepatitis B
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Virological Response to Conventional Interferon Therapy Combined with Ribavirin against Various HCV Genotypes in Khyber Pakhtunkhwa, Pakistan
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Combination of Pegylated Interferon and Nucleos(t)ide Therapy: Toward a Cure of Hepatitis B Virus Infection?
Gut and Liver
2016 .01
-
Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era
Gut and Liver
2017 .07
-
Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study
Gut and Liver
2017 .01
-
Interferon-Alpha Induced Severe Hypothyroidism Followed by Graves’ Disease in a Patient Infected with Hepatitis C Virus
International Journal of Thyroidology
2015 .01
-
Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims’ Data
Gut and Liver
2017 .01
-
The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms
Blood Research
2021 .04
-
The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms
Blood Research
2021 .01
-
Mental Disorders and Interferon Nontreatment in Hepatitis C Virus Infection-a Population Based Cohort Study
PSYCHIATRY INVESTIGATION
2020 .01
-
Association of Changes in Mood Status and Psychosocial Well-Being with Depression During Interferon-Based Treatment for Hepatitis C
PSYCHIATRY INVESTIGATION
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0